Kimberly-Clark May Sell Assets to Clear $40 Billion Kenvue Deal
- Kimberly-Clark prepares concessions for EU antitrust review of $40 billion Kenvue deal
- Australia mandated sale of Stayfree and Carefree brands to preserve competition
- Stock down 21.09% over 12 months despite trading near oversold RSI levels
- Analyst consensus remains Hold with average price target of $112.43

*this image is generated using AI for illustrative purposes only.
Kimberly-Clark Corp. (NYSE: KMB) is preparing concessions to address European Union antitrust concerns regarding its proposed $40 billion acquisition of Kenvue Inc. (NYSE: KVUE). The company may need to divest assets to secure regulatory approval for the transaction.
The European Commission is expected to formally outline its competition concerns this week, according to Reuters. Kimberly-Clark could offer remedies before the preliminary review ends on Sept. 29. Failure to do so could trigger an in-depth investigation lasting approximately four months.
Regulatory Landscape
Australia has already imposed conditions on the deal. The Australian Competition and Consumer Commission approved the acquisition subject to the sale of Kenvue’s Stayfree and Carefree period-care brands to an approved buyer. This divestiture aims to preserve competition in a market previously dominated by three major suppliers: Kimberly-Clark, Kenvue, and Essity.
Market Performance
Kimberly-Clark shares rose 0.33% to $99.00 in premarket trading, while Kenvue shares gained 0.28% to $17.97. Broader market sentiment also improved, with Nasdaq futures up 0.54% and S&P 500 futures up 0.32%.
Despite the morning gains, Kimberly-Clark stock has fallen 21.09% over the past 12 months. The stock remains in a longer-term downtrend, trading below all four major moving averages.
| Metric | Value | Status |
|---|---|---|
| Current Price | $99.00 | Down 21.09% (12M) |
| 20-Day SMA | $106.06 | Stock is 6.7% below |
| 50-Day SMA | $108.28 | Stock is 8.6% below |
| 100-Day SMA | $104.43 | Stock is 5.2% below |
| 200-Day SMA | $103.09 | Stock is 4.0% below |
The relative strength index stands at 30, placing the stock near oversold territory. Resistance sits near $111.50, while support is around $93, close to the 52-week low of $92.42.
Analyst Outlook
The stock carries a Hold consensus rating with an average price forecast of $112.43. Recent analyst actions include:
- Piper Sandler maintained an Overweight rating and lowered its price forecast to $118 on Sept. 11.
- Wells Fargo maintained Equal-Weight and cut its forecast to $105 on Sept. 10.
- UBS maintained Neutral and raised its forecast to $116 on Aug. 5.
What the Numbers Show
Kimberly-Clark’s Benzinga Edge scorecard reveals a divergence between fundamentals and momentum. The company scores 98.09 for Quality and 84.27 for Growth, yet its Momentum score is just 18.66. This gap highlights how prolonged price weakness has overshadowed strong underlying business metrics.
Which specific assets or business units might Kimberly-Clark be forced to divest to satisfy the European Commission's antitrust concerns?
How could a potential four-month in-depth investigation by the EU impact the timeline and final valuation of the $40 billion deal?
Will other major regulators, such as the US FTC or UK CMA, impose similar divestiture conditions following Australia's precedent?






























